 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12345678910111213...203204» |
- | Humira (adalimumab) / AbbVie
Biomarker, Retrospective data, Journal: Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease. (Pubmed Central) - Jun 8, 2024
In comparison to acute-resolved patients, chronic-recurrent patients exhibited poorer initial BCVA and a significantly increased incidence of "sunset glow fundus." Older age at onset and the occurrence of "sunset glow fundus" at diagnosis are crucial predictive factors for VKH patients progressing to the chronic recurrent phase. ADA effectively alleviates refractory VKH disease and is generally well-tolerated.
- | Humira (adalimumab) / AbbVie
Journal: Letter to the Editor: Comment on Raad et al's "Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience". (Pubmed Central) - Jun 7, 2024
ADA effectively alleviates refractory VKH disease and is generally well-tolerated. No abstract available
- || Review, Journal: Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review. (Pubmed Central) - Jun 7, 2024
However, differences in baseline characteristics or comorbidities were found, suggesting race or ethnic background should be considered when treatment is prescribed in psoriasis or atopic dermatitis. Although no significant SOC participant differential response to treatment were found, large-scale randomized controlled trials investigating comparable treatment outcomes and stratifying results by SOC population in atopic dermatitis and psoriasis are warranted to confirm these findings.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Study on Cloning and Expression of TNF-? Variants in E. coli: Production, Purification, and Interaction with Anti-TNF-? Inhibitors. (Pubmed Central) - Jun 7, 2024
The high binding efficiency of sTNF-? with adalimumab, etanercept, and infliximab, evidenced in this study supports the feasibility of its use in therapeutic applications, contributing to more sustainable, cost-effective, and independent healthcare system.
- | Humira (adalimumab) / AbbVie
Retrospective data, Journal: Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol. (Pubmed Central) - Jun 7, 2024
Additionally, this report provides an extensive review of the existing literature on drug-induced AHA, with a special emphasis on cases linked to immunomodulatory medications. Through this two-pronged approach, our report aims to enhance understanding and awareness of this severe complication among healthcare providers, promoting timely diagnosis and intervention.
- | Humira (adalimumab) / AbbVie
Journal, Adherence: High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease. (Pubmed Central) - Jun 6, 2024
High refill-adherence to adalimumab therapy was associated with less active disease in IBD patients. Our results confirm the relevance of good adherence to adalimumab for achieving optimal treatment results, which may limit the need for switching to more expensive biologics.
- | Humira (adalimumab) / AbbVie
Journal: Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography. (Pubmed Central) - Jun 6, 2024
Decreased CVI in NIU and NU eyes indicates that systemic inflammation affects the choroidal vasculature and perfusion both in the presence and absence of ocular involvement. Although CVI may be used as a possible novel tool in monitoring ocular involvement and progression of NIU, CVI does not seem to be a biomarker for treatment monitoring in NIU.
- || Humira (adalimumab) / AbbVie
Review, Journal: The Spectrum of Papillophlebitis. (Pubmed Central) - Jun 6, 2024
blockers in the management of patients with recalcitrant papillophlebitis and non-responsive CME. Further studies are needed in order to thoroughly investigate the molecular background of papillophlebitis and clinical outcomes associated with this class of medications.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis. (Pubmed Central) - Jun 6, 2024
is rarely reported in the literature. We report a 44-year-old woman who developed erythrodermic psoriasis associated with diffuse alopecia during her treatment with adalimumab for palmoplantar pustulosis.
- | Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Journal, HEOR, Real-world evidence, Real-world: Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource. (Pubmed Central) - Jun 3, 2024
We provide real-world evidence to guide biologic selection and sequencing in a range of common scenarios. Our findings challenge current guidelines regarding drug selection after loss of response to first anti-TNF treatment.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases. (Pubmed Central) - Jun 3, 2024
Higher adalimumab levels were associated with a better response and improved drug survival for all diagnoses, with a suggested lower threshold of 6.0?mg/l for RA/PsA. This finding, the large variability in drug levels among patients receiving standard adalimumab dose and the high proportion of patients developing ADAbs encourages further investigations into the potential role of therapeutic drug monitoring of adalimumab.
- | Humira (adalimumab) / AbbVie
Journal: Long-Term Outcomes of Adalimumab Treatment in Conventional Treatment-Resistant Serpiginous Choroiditis. (Pubmed Central) - Jun 3, 2024
Our findings suggest a promising role for ADA in halting the progression of SC and have implications for improving outcomes. Despite the evidence in the literature at the level of case reports, ADA can be used effectively with close monitoring for potential risks.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease. (Pubmed Central) - Jun 3, 2024
This study demonstrates a robust association between serum concentrations of IFX, ADA, Alb, and CRP and primary endoscopic response in active CD patients. Importantly, the TDM- and laboratory marker-based nomogram may be used to evaluate the primary endoscopic response to anti-TNF therapy, especially for optimizing treatment strategies and switching therapy in CD patients.
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective. (Pubmed Central) - Jun 3, 2024
(TNF-?) inhibitors, adalimumab, infliximab, and etanercept, are well studied in this patient population, and in some cases, HS was unresponsive to them...Also, golimumab showed promise in treating recalcitrant HS after the failure of other treatments, such as adalimumab and anti-interleukin-1. CPZ and golimumab can be efficacious treatment options for moderate-to-severe HS, especially in patients who are unresponsive to other TNF inhibitors, such as adalimumab.
- | Humira (adalimumab) / AbbVie
Journal: The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial. (Pubmed Central) - Jun 3, 2024
P4
However, if a short course of biologics can rapidly suppress inflammation allowing treatment to be withdrawn and response maintained on methotrexate, this may be a cost-effective model for early use. ClinicalTrials.gov (NCT03739853) and EudraCT (2017-004542-24).
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy. (Pubmed Central) - Jun 2, 2024
In our study, patients receiving Etanercept, Adalimumab and Tocilizumab had no increased risk of TB infection. Only 0.3% of patients treated with Adalimumab and 0.9% of patients treated with Etanercept converted to a positive IGRA during therapy.
- || Review, Journal: The Dermatology Life Quality Index (DLQI) as the Primary Outcome in Randomised Clinical Trials: A systematic review. (Pubmed Central) - May 31, 2024
Only 0.3% of patients treated with Adalimumab and 0.9% of patients treated with Etanercept converted to a positive IGRA during therapy. This study provides evidence for use of the DLQI as primary outcome in clinical trials to inform researchers' and clinicians' decisions for its further use.
- Idacio (adalimumab-aacf) / Fresenius Kabi, Humira (adalimumab) / AbbVie
DRUG PERSISTENCE WITH THERAPY OF ADALIMUMAB BIOSIMILAR, MSB11022, IN RHEUMATOLOGIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_4568;
This study provides evidence for use of the DLQI as primary outcome in clinical trials to inform researchers' and clinicians' decisions for its further use. The evidence suggests that drug persistence of adalimumab biosimilar, MSB11022, was high in both treatment-na
- Humira (adalimumab) / AbbVie
EXPLORING THE RELATIONSHIP BETWEEN ADALIMUMAB THROUGH LEVELS AND FIVE PATIENT REPORTED OUTCOME MEASURES IN RHEUMATOID ARTHRITIS THE LADDER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4559;
In addition, this study emphasizes the importance of considering gender differences in RA treatment with adalimumab. To strengthen our findings and underscore the significance of PROMs in RA patient care, further research with larger sample sizes are needed.
- Humira (adalimumab) / AbbVie
THE CARBON FOOTPRINT OF ADALIMUMAB BIOSIMILARS THROUGH THEIR LIFE CYCLE () - May 29, 2024 - Abstract #EULAR2024EULAR_4525;
Comparatively, the syringe halves the emissions compared to the pen. Our results will help both manufacturers and prescribers decarbonize healthcare.
- BIOLOGIC AND TARGETED SYNTHETIC DRUGS MANAGEMENT IN RHEUMATOID ARTHRITIS AFTER IMPLEMENTATION OF A COMMUNITY OPTIMIZATION PROTOCOL () - May 29, 2024 - Abstract #EULAR2024EULAR_4504;
One out of four patients decreased the dose or increased the drug administration interval. Consequently, a considerable reduction in costs was observed.
- Humira (adalimumab) / AbbVie
PREDICTORS OF RECURRENCE IN PEDIATRIC PATIENTS WITH NON-INFECTIOUS UVEITIS UNDERGOING ADALIMUMAB TAPERING: AN INTERNATIONAL MULTICENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4384;
Caucasian race and fast tapering were associated with a higher risk of recurrences. Therefore, a strict follow-up for these patients should be advisable, and a gradual ADA taper is recommended.
- REAL WORLD DATA FROM A SINGLE CENTER: SURVIVAL RATES OF TNFi AS FIRST AND SECOND LINE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4227;
TNFi display good overall survival rates as first line treatment among PsA with inadequate response to cDMARDs. Female gender and peripheral involvement are independent risk factors for early secondary inefficacy to first TNFi.
- Humira (adalimumab) / AbbVie
PREDICTIVE FACTORS OF THE FIRST BDMARD SWITCH IN PSORIATIC ARTHRITIS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_4223;
The increase in inflammatory parameters at the start of the first bDMARD was a predictive factor of the switch in our population. In the univariate analysis, there appears to be a tendency for an increased probability of switching in patients with heavy work, young age at diagnosis, AR-like subtype and shorter time to progression until bDMARD start.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
IMPACT OF URICEMIA ON PSORIATIC ARTHRITIS, AND ON SAFETY AND CLINICAL RESPONSE TO UPADACITINIB AND ADALIMUMAB: POST-HOC ANALYSIS OF PHASE III STUDIES () - May 29, 2024 - Abstract #EULAR2024EULAR_4204;
The observed differential clinical profile and comorbidities, which confirm previous studies 3 , underscore the value of assessing serum urate levels in PsA pts. Pts with HU were more prone to develop hypertension or diabetes mellitus.
- Tremfya (guselkumab) / J&J
COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4174;
Adults with PsA newly initiated on guselkumab or the first observed SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or SC golimumab) between 7/14/2020 and 3/31/2022 were selected from the IQVIA TM Health Plan Claims Data. This real-world study assessing treatment persistence in PsA using administrative claims data demonstrated that guselkumab was associated with significantly longer on-label persistence through 12 months versus SC TNFi.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
WHY DO CLINICIANS REQUEST BDMARD DRUG LEVELS? RETROSPECTIVE REVIEW OF OVER 8000 REQUESTS () - May 29, 2024 - Abstract #EULAR2024EULAR_4054;
They test most frequently in PsA, perhaps indicating greater uncertainty of disease activity when compared to RA. Use of TDM in rheumatology is dwarfed by the request volume for gastroenterology.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
TUBERCULOSIS UNDER BIOTHERAPY IN CHRONIC INFLAMMATORY RHEUMATISMS: A COHORT STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4052;
The frequency of tuberculosis under biologic therapy, although relatively low at 4% in our study, nevertheless underscores the need for close monitoring and thorough pre-treatment assessment before initiating this type of therapy. The results demonstrate that, despite precautions taken, cases of tuberculosis can occur, highlighting the complexity of managing this population of immunocompromised patients.
- Humira (adalimumab) / AbbVie
PERCEIVED NEED FOR TREATMENT IS ASSOCIATED WITH PATIENT SATISFACTION AFTER A SWITCH TO A BIOSIMILAR; HEALTH LITERACY IS OFTEN LIMITED: A PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY OF 232 PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_4020;
P
The level of health literacy was problematic or insufficient in around half of these patients with long-standing disease and long-standing biologic use. These results suggest that although satisfaction with switching was generally high, beliefs and concerns remain important and could lead to non-adherence.
- Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
PATIENT SATISFACTION AND EXPERIENCE AFTER A SWITCH TO AN ADALIMUMAB BIOSIMILAR WITH HIGH CONCENTRATION AND CITRATE-FREE: RESULTS FROM A MULTICENTRIC PROSPECTIVE REAL-LIFE STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4019;
P
The global experience of switching to CT-P17 was positive with an overall improvement in injection tolerance. Injection volume was an independent factor associated with a successful experience.
- INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_4000;
It appears that the risk of relapse of inflammation in patients receiving bDMARDs is high. Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment.
- Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
EXPLORING THE SAFETY AND EFFECTIVENESS OF BIOSIMILARS BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS DURING PREGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_3990;
Particularly, no congenital abnormalities nor perinatal complications occurred. Discontinuation at positive pregnancy test or a delayed start during pregnancy of B-bDMARDs seems to be associated with disease flares and preterm birth.
- Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
ECONOMIC IMPACT AND CLINICAL OUTCOMES WITH THE SWITCH TO BIOSIMILARS IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS IN A SPECIALIZED CENTER IN BOGOT () - May 29, 2024 - Abstract #EULAR2024EULAR_3982;
Background: Biosimilars may represent an important opportunity to improve allocation efficiency in the biologics market due to their lower cost compared to that of originator biologics and are expected to generate significant savings for healthcare systems in even more countries of emerging economies Objectives: Determine the economic impact of the switch to biosimilars in a cohort of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) who attend a comprehensive management program at Risk of Fracture S.A-CAYRE and describe their clinical characteristics Descriptive observational study of a cohort of adult patients diagnosed with RA and EAS who had been receiving the reference products and switched to treatment with the biosimilars available in the country (rituximab, adalimumab, infliximab and etanercept) over a time horizon of 1 year...Regarding concomitant medications in RA, 28.1% receive methotrexate and 20% leflunomide, with 24% receiving biosimilars in monotherapy... With the switch to biosimilars in this cohort of patients with RA and SpA, significant savings are evident for the health system while maintaining adequate control of the disease, without an increase in adverse effects.
- EFFICACY OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENT OF SARCOIDOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3944;
Meta-analyses of b/tsDMARDs placebo controlled trial data suggests an overall inefficacy in meeting studies primary outcomes, whilst pooled data from placebo controlled and single arm studies examining lung function has demonstrated a small and clinically non-significant increase in FVC%. Limited studies warrant caution in interpreting these findings.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
TIME AND TREATMENT AS KEY FACTORS IN THE DEVELOPMENT OF UVEITIS IN JUVENILE IDIOPATHIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3936;
More than half of the patients developed uveitis while not receiving systemic treatment. We observed that those receiving methotrexate as monotherapy had a higher frequency of uveitis compared to other treatments.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
LONG-TERM EFFICACY OF ETANERCEPT AND ADALIMUMAB IN A COHORT OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3927;
Long-term treatment with ETN and ADA has been shown to be effective and safe for patients with JIA, as evidenced by the high retention rate recorded in our cohort. Most patients maintain current therapy for years to preserve remission status.
- Orencia (abatacept) / BMS, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT () - May 29, 2024 - Abstract #EULAR2024EULAR_3867;
Lower antibody levels were associated with rituximab-therapy and older age. Disease activity, csDMARD or GCS use had no effect.
- DISEASE FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING COVID-19 BREAKTHROUGH INFECTION: RESULT FROM COVAD E-SURVEY STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3841;
Disease activity, csDMARD or GCS use had no effect. Younger age (odds ratio (OR): 0.98, 95% CI: 0.96
- WHAT IS THE TRUTH? - COMPARISON OF REACTIONS AND ADVERSE EVENTS BETWEEN JAK INHIBITORS AND ANTI-TNFS - REAL LIFE EXPERIENCE () - May 29, 2024 - Abstract #EULAR2024EULAR_3757;
No major cardiovascular events or thrombotic events were found in a great population of patients using JAKs inhibitors in recent two years. Larger studies are required in the Latin American population to confirm these results.
- Humira (adalimumab) / AbbVie
WHOLE BLOOD-BASED TRANSCRIPTOMIC BIOMARKERS FOR PREDICTING ADALIMUMAB TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS IDENTIFIED THROUGH MACHINE LEARNING () - May 29, 2024 - Abstract #EULAR2024EULAR_3676;
Analysis of whole blood transcriptomics reveals biomarkers underlying adalimumab response in RA, emphasizing immune activity's vital role. These findings highlights potential for precision medicine in RA, now require external validation.
- VIRAL INFECTIONS AMONG PATIENTS RECEIVING BIOLOGICS FOR RHEUMATIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_3673;
Biological therapies, especially TNF alpha inhibitors, may lead to an increased risk of viral infections. These infections were reported in 6% of our patients.
- Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3635;
P3
This post hoc analysis shows that meaningful improvements in PROs (VAS pain, FACIT-Fatigue and HAQ-DI) with FIL in RA at the patient level occur early and are sustained over time. These data help to strengthen the scientific understanding of the unique clinical and PRO benefits with FIL treatment relevant to patients.
- PREDICTIVE FACTORS FOR GOOD RESPONSE TO RHEUMATOID ARTHRITIS WITH BIOLOGICAL TARGETED THERAPIES () - May 29, 2024 - Abstract #EULAR2024EULAR_3594;
These data help to strengthen the scientific understanding of the unique clinical and PRO benefits with FIL treatment relevant to patients. All patients had active RA before biotherapy with a DAS28 score average initial of 5.42
- BHV-1300 / Biohaven, Humira (adalimumab) / AbbVie
PHARMACOKINETICS OF ADALIMUMAB IN CYNOMOLGUS MONKEYS FOLLOWING DOSING WITH BHV-1300, A FIRST-IN-CLASS MOLECULAR DEGRADER OF IgG () - May 29, 2024 - Abstract #EULAR2024EULAR_3587;
These results represent a key differentiating feature from neonatal Fc receptor inhibitors, which adversely affect the exposure to and effectiveness of, and cannot be co-administered with, Fc-containing biologics, including adalimumab. Moreover, BHV-1300 potentially offers a significantly improved benefit-risk based on other important mechanistic advantages including rapid onset of IgG-lowering, shortened time to maximal effect, depth of IgG lowering, brief period of exposure, potential for reduced immunosuppression, and lack of effects on albumin, cholesterol or triglycerides.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING TNF INHIBITORS IN REAL LIFE IN FRANCE IN 2016-2022 ARE DIFFERENT FROM PATIENTS INCLUDED IN SIMILAR COHORTS AND IN CLINICAL TRIALS. DATA FROM THE ART-SFR REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3583;
P=N/A
Given the design of the registry, their characteristics can be considered representative of those of patients initiating TNFi for RA in France. Most patients in the registry were treated in accordance with recommendations.
- Humira (adalimumab) / AbbVie
NON-MEDICAL SWITCH OF BIOLOGIC DRUGS IN PATIENTS WITH RHEUMATIC DISEASE () - May 29, 2024 - Abstract #EULAR2024EULAR_3572;
Patients with SpA were the most affected. Golimumab has the preferred application device.
- Humira (adalimumab) / AbbVie
EXPLORING ADALIMUMAB TROUGH LEVELS AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS THE RADAR STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3502;
Although no statistically significant correlation between adalimumab exposure and DAS was observed, a notable visual difference hints at potential clinical significance, warranting further investigation. Additionally, this study indicates that RA patients in remission on adalimumab can potentially extend dosing intervals without an elevated risk of disease exacerbation.
- Humira (adalimumab) / AbbVie
DRUG SURVIVAL ON FIRST BIOLOGIC THERAPY AMONG ELDERLY-ONSET RHEUMATOID ARTHRITIS PATEINTS COMPARED TO YOUNG-ONSET PATIENTS: A POPULATION-BASED COHORT STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3479;
Figure 1. Study population.
- DRUG SURVIVAL AND PREDICTOR FACTORS FOR DISCONTINUATION OF FIRST-LINE BIOLOGIC THERAPY: DATA FROM A REAL-WORLD SINGLE CENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3478;
Longer disease duration and higher disease activity at baseline, as well as more comorbidities and extra-articular manifestations were associated with early discontinuation of the first bDMARD therapy. RF and ACPA negativity predicted better drug survival.
- Humira (adalimumab) / AbbVie
CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3457;
MOA switchers showed greater prevalence of arterial hypertension as well as higher titles of ESR and higher disease activity at baseline according to DAS28-ESR three variables. These findings may influence therapeutic decisions, but further investigation is needed.